Swiss Re AG
DUS:SR9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swiss Re AG
DUS:SR9
|
CH |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
KR |
|
I
|
ING Groep NV
SWB:INN1
|
NL |
|
Volvo AB
F:VOL4
|
SE |
|
C
|
Credit Suisse Group AG
XHAM:CSX
|
CH |
|
Aspen Pharmacare Holdings Ltd
F:LDZU
|
ZA |
|
K
|
Konami Holdings Corp
F:KOA
|
JP |
|
C
|
Coca-Cola Co
DUS:CCC3
|
US |
|
J
|
Japan Tobacco Inc
OTC:JAPAY
|
JP |
|
B
|
Budweiser Brewing Company APAC Ltd
OTC:BDWBF
|
HK |
Wall St Price Targets
SR9 Price Targets Summary
Swiss Re AG
According to Wall Street analysts, the average 1-year price target for SR9 is 139.53 EUR with a low forecast of 119.99 EUR and a high forecast of 181.44 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SR9's stock price target?
Price Target
139.53
EUR
According to Wall Street analysts, the average 1-year price target for SR9 is 139.53 EUR with a low forecast of 119.99 EUR and a high forecast of 181.44 EUR.
What is the Revenue forecast for Swiss Re AG?
Projected CAGR
3%
Over the last 14 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 3 years is 3%.
What is the Net Income forecast for Swiss Re AG?
Projected CAGR
1%
Over the last 14 years, the compound annual growth rate for Net Income has been 4%. The projected CAGR for the next 3 years is 1%.
